Unternehmensübersicht
DBV Technologies S.A. operates as a clinical-stage biopharmaceutical entity focused on the research and development of epicutaneous immunotherapy products specifically within the French market. The company's primary asset, Viaskin Peanut, has successfully completed Phase 3 clinical trials for the treatment of peanut allergy, representing a significant milestone in its product pipeline. This enterprise functions within the Healthcare sector, specifically the Biotechnology industry, which is characterized by high R&D expenditures and long development cycles before commercialization. With a market capitalization of $1.11 billion, an annual revenue of $5.50 million, and a workforce of 117 employees, the company maintains a relatively small scale typical of pre-commercialization biotech firms. The disparity between the substantial market capitalization and the modest revenue base indicates that the market is pricing in significant future potential rather than current operational performance, reflecting the high-risk, high-reward nature of the biotechnology sector where value is often derived from pipeline assets rather than immediate cash flows.
Finanzielle Gesundheit
The company reported revenue of $5.50 million over the trailing twelve months, while the net income stands at -$125.13 million, highlighting a severe structural deficit where operating expenses vastly outweigh revenue generation. The absence of reported EBITDA figures further underscores the current stage of development where revenue is not yet sufficient to cover the substantial costs of research and clinical trials. Free cash flow is reported at -$51.06 million, indicating a significant cash outflow that necessitates continuous capital raising or reliance on existing reserves to fund operations. Despite these outflows, the company holds $69.84 million in cash against $7.69 million in debt, suggesting a balance sheet that remains conservative in terms of solvency despite the leverage implied by the business model. The debt-to-equity ratio of 14.55 is a critical metric that, while numerically high, must be viewed in the context of cash-rich, non-income-producing biotech assets where equity value often exceeds book value. The current ratio of 1.80 indicates that the company possesses sufficient liquid assets to cover short-term liabilities, providing a buffer against immediate liquidity pressures. Furthermore, the return on equity is -234.1% and the return on assets is -77.3%, metrics that reveal that management is currently utilizing shareholder and asset bases to generate losses rather than profits, a common but financially challenging characteristic of clinical-stage development.
Bewertungsanalyse
The trailing twelve-month P/E ratio is listed as N/A due to the negative earnings, while the forward P/E is reported at -76.67, a figure that implies the market expects earnings to remain negative or for the stock to trade at a premium based on pipeline value rather than current profitability. The price-to-book ratio of 51.81 suggests a substantial market premium over the book value, indicating that investors are willing to pay significantly more than the net asset value for the company's intangible pipeline assets. The price-to-sales ratio of 202.28 and the N/A EV/EBITDA metric further illustrate that traditional valuation multiples are distorted by the lack of earnings and the high value placed on future commercialization potential. Regarding price volatility, the 52-week high is $26.18 and the 52-week low is $3.91; without a specific current price provided in the facts, the position relative to this range cannot be calculated, but the wide spread indicates high historical volatility. The beta value of -0.21 is a distinct anomaly for an equity instrument, suggesting a negative correlation to the broader market or a statistical artifact that implies price movements are not synchronized with general market trends.
Growth & Income
Revenue growth year-over-year is reported at 158.8%, demonstrating a rapid expansion in sales, whereas earnings growth is N/A due to the company's net loss status. The divergence between revenue expansion and earnings performance implies that top-line growth is occurring without corresponding profitability, a typical trajectory for companies scaling up before reaching commercial profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders but instead reinvests all available resources into research and development. Consequently, the overall growth and income profile is defined by aggressive revenue expansion funded by cash reserves rather than by shareholder returns or current earnings generation, positioning the stock as a pure play on the future success of the Viaskin Peanut product.